SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
NCT ID: NCT02214134
Last Updated: 2025-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
539 participants
OBSERVATIONAL
2015-05-22
2021-05-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Profiling Project
NCT04025515
Prospective Data Collection Initiative on Thoracic Malignancies
NCT06996249
Thoracoscopic Laser Speckle Contrast Imaging for Segment Resections
NCT05545085
Thoracic Tumours Register
NCT02941458
Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE
NCT05649046
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lung cancer
Patients with diagnosis of lung cancer at any stage
Tumour markers testing
Malignant pleural mesothelioma
Patients with diagnosis of malignant pleural mesothelioma at any stage
Tumour markers testing
Thymic malignancy
Patients with diagnosis of thymic malignancy at any stage
Tumour markers testing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tumour markers testing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mandatory availability of adequate Human Biological Material (HBM): FFPE tissue sample from the primary tumor, recurrent tumor, metastasis, obtained at the time of primary surgery or biopsy; minimal amount requested is detailed in the HBM guidelines; inclusion of samples taken at any recurrence diagnosed during follow-up is strongly encouraged but optional;
* Centrally performed confirmation of tumor tissue adequacy in terms of quality/ quantity for central screening;
* Age ≥ 18 years;
* At least three months life-expectancy;
* Written informed consent according to ICH/GCP and national/local regulations.
Exclusion Criteria
* Active hepatitis B/C or HIV;
* Any secondary malignancy;
* Any severe organ dysfunction or other comorbidities that may prevent the inclusion into clinical trials.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ETOP IBCSG Partners Foundation
NETWORK
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Benjamin Besse, MD, PhD
Role: STUDY_CHAIR
Gustave Roussy, Cancer Campus, Grand Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Brussels, , Belgium
Universitair Ziekenhuis Antwerpen
Edegem, , Belgium
U.Z. Leuven - Campus Gasthuisberg
Leuven, , Belgium
CHU de Lyon - Hopital Louis Pradel
Lyon, , France
Assistance Publique - Hopitaux de Marseille - Hopital Nord
Marseille, , France
CHU Toulouse - Hopital Larrey
Toulouse, , France
Gustave Roussy Cancer Campus
Villejuif, , France
St. James's Hospital
Dublin, , Ireland
Ospedale S. Luigi Gonzaga - Universita Di Torino
Torino, , Italy
Medical University Of Gdansk
Gdansk, , Poland
University Clinic Golnik
Golnik, , Slovenia
Hospital General Vall D'Hebron
Barcelona, , Spain
Hospital Universitario 12 De Octubre
Madrid, , Spain
Centre Hospitalier Universitaire Vaudois - Lausanne
Lausanne, , Switzerland
Centre Hospitalier Universitaire Vaudois - Lausanne
Lausanne, , Switzerland
Royal Marsden Hospital - Kingston Hospital
Kingston upon Thames, , United Kingdom
Royal Marsden Hospital - Chelsea, London
London, , United Kingdom
Royal Marsden Hospital - Sutton, Surrey
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EORTC-1335-LCG-PBG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.